Table of Contents Author Guidelines Submit a Manuscript
Journal of Diabetes Research
Volume 2016, Article ID 6264149, 10 pages
http://dx.doi.org/10.1155/2016/6264149
Review Article

Metainflammation in Diabetic Coronary Artery Disease: Emerging Role of Innate and Adaptive Immune Responses

1Department of Genetics, Dr. ALM. PG. IBMS, University of Madras, Chennai 600113, India
2AU-KBC Research Centre, MIT Campus of Anna University, Chennai 600044, India

Received 19 May 2016; Accepted 19 July 2016

Academic Editor: Zhenwu Zhuang

Copyright © 2016 Vivekanandhan Aravindhan and Haridoss Madhumitha. This is an open access article distributed under the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.

Linked References

  1. D. Aronson and E. R. Edelman, “Coronary artery disease and diabetes mellitus,” Heart Failure Clinics, vol. 12, no. 1, pp. 117–133, 2016. View at Publisher · View at Google Scholar · View at Scopus
  2. F. Laugerette, C. Vors, N. Peretti, and M.-C. Michalski, “Complex links between dietary lipids, endogenous endotoxins and metabolic inflammation,” Biochimie, vol. 93, no. 1, pp. 39–45, 2011. View at Publisher · View at Google Scholar · View at Scopus
  3. W. Ebstein, “Invited comment on W. Ebstein: on the therapy of diabetes mellitus, in particular on the application of sodium salicylate,” Journal of Molecular Medicine, vol. 80, no. 10, pp. 618–619, 2002. View at Google Scholar
  4. N. Dali-Youcef, M. Mecili, R. Ricci, and E. Andrès, “Metabolic inflammation: connecting obesity and insulin resistance,” Annals of Medicine, vol. 45, no. 3, pp. 242–253, 2013. View at Publisher · View at Google Scholar · View at Scopus
  5. D. Tousoulis, M. Charakida, and C. Stefanadis, “Endothelial function and inflammation in coronary artery disease,” Heart, vol. 92, no. 4, pp. 441–444, 2006. View at Publisher · View at Google Scholar · View at Scopus
  6. M. S. Shah and M. Brownlee, “Molecular and cellular mechanisms of cardiovascular disorders in diabetes,” Circulation Research, vol. 118, no. 11, pp. 1808–1829, 2016. View at Publisher · View at Google Scholar
  7. R. Virmani, A. P. Burke, and F. Kolodgie, “Morphological characteristics of coronary atherosclerosis in diabetes mellitus,” The Canadian Journal of Cardiology, vol. 22, pp. 81B–84B, 2006. View at Publisher · View at Google Scholar
  8. M. Naghavi, P. Libby, E. Falk et al., “From vulnerable plaque to vulnerable patient: a call for new definitions and risk assessment strategies: part I,” Circulation, vol. 108, no. 14, pp. 1664–1672, 2003. View at Publisher · View at Google Scholar
  9. R. Ross, “Atherosclerosis—an inflammatory disease,” The New England Journal of Medicine, vol. 340, no. 2, pp. 115–126, 1999. View at Publisher · View at Google Scholar · View at Scopus
  10. J. Danesh, R. Collins, and R. Peto, “Chronic infections and coronary heart disease: is there a link?” The Lancet, vol. 350, no. 9075, pp. 430–436, 1997. View at Publisher · View at Google Scholar · View at Scopus
  11. T. Kawai and S. Akira, “The roles of TLRs, RLRs and NLRs in pathogen recognition,” International Immunology, vol. 21, no. 4, pp. 317–337, 2009. View at Publisher · View at Google Scholar · View at Scopus
  12. O. Takeuchi and S. Akira, “Pattern recognition receptors and inflammation,” Cell, vol. 140, no. 6, pp. 805–820, 2010. View at Publisher · View at Google Scholar · View at Scopus
  13. V. Aravindhan, V. Mohan, J. Surendar et al., “Effect of filarial infection on serum inflammatory and atherogenic biomarkers in coronary artery disease (CURES-121),” The American Journal of Tropical Medicine and Hygiene, vol. 86, no. 5, pp. 828–833, 2012. View at Publisher · View at Google Scholar · View at Scopus
  14. V. Aravindhan, V. Mohan, J. Surendar et al., “Decreased prevalence of lymphatic filariasis among diabetic subjects associated with a diminished pro-inflammatory cytokine response (CURES 83),” PLoS Neglected Tropical Diseases, vol. 4, no. 6, article e707, 2010. View at Publisher · View at Google Scholar · View at Scopus
  15. J. Surendar, V. Aravindhan, M. M. Rao, A. Ganesan, and V. Mohan, “Decreased serum interleukin-17 and increased transforming growth factor-β levels in subjects with metabolic syndrome (Chennai Urban Rural Epidemiology Study-95),” Metabolism: Clinical and Experimental, vol. 60, no. 4, pp. 586–590, 2011. View at Publisher · View at Google Scholar · View at Scopus
  16. K. Asehnoune, D. Strassheim, S. Mitra, J. Y. Kim, and E. Abraham, “Involvement of reactive oxygen species in toll-like receptor 4-dependent activation of NF-κB,” The Journal of Immunology, vol. 172, no. 4, pp. 2522–2529, 2004. View at Publisher · View at Google Scholar · View at Scopus
  17. H. Bilak, S. Tauszig-Delamasure, and J.-L. Imler, “Toll and Toll-like receptors in Drosophila,” Biochemical Society Transactions, vol. 31, no. 3, pp. 648–651, 2003. View at Publisher · View at Google Scholar · View at Scopus
  18. M. Gangloff, A. N. R. Weber, R. J. Gibbard, and N. J. Gay, “Evolutionary relationships, but functional differences, between the Drosophila and human Toll-like receptor families,” Biochemical Society Transactions, vol. 31, no. 3, pp. 659–663, 2003. View at Publisher · View at Google Scholar · View at Scopus
  19. F. Liu, W. Lu, Q. Qian, W. Qi, J. Hu, and B. Feng, “Frequency of TLR 2, 4, and 9 gene polymorphisms in Chinese population and their susceptibility to type 2 diabetes and coronary artery disease,” Journal of Biomedicine and Biotechnology, vol. 2012, Article ID 373945, 7 pages, 2012. View at Publisher · View at Google Scholar · View at Scopus
  20. K. Singh, N. K. Agrawal, S. K. Gupta, G. Mohan, S. Chaturvedi, and K. Singh, “Increased expression of endosomal members of toll-like receptor family abrogates wound healing in patients with type 2 diabetes mellitus,” International Wound Journal, 2015. View at Publisher · View at Google Scholar · View at Scopus
  21. K. Ashida, K. Miyazaki, E. Takayama et al., “Characterization of the expression of TLR2 (toll-like receptor 2) and TLR4 on circulating monocytes in coronary artery disease,” Journal of Atherosclerosis and Thrombosis, vol. 12, no. 1, pp. 53–60, 2005. View at Publisher · View at Google Scholar · View at Scopus
  22. D. Pisetsky, “Cell death in the pathogenesis of immune-mediated diseases: the role of HMGB1 and DAMP-PAMP complexes,” Swiss Medical Weekly, vol. 141, Article ID w13256, 2011. View at Google Scholar · View at Scopus
  23. M. R. Dasu, S. Devaraj, S. Park, and I. Jialal, “Increased toll-like receptor (TLR) activation and TLR ligands in recently diagnosed type 2 diabetic subjects,” Diabetes Care, vol. 33, no. 4, pp. 861–868, 2010. View at Publisher · View at Google Scholar · View at Scopus
  24. L. Brånén, L. Hovgaard, M. Nitulescu, E. Bengtsson, J. Nilsson, and S. Jovinge, “Inhibition of tumor necrosis factor-α reduces atherosclerosis in apolipoprotein E knockout mice,” Arteriosclerosis, Thrombosis, and Vascular Biology, vol. 24, no. 11, pp. 2137–2142, 2004. View at Publisher · View at Google Scholar · View at Scopus
  25. M. J. Song, K. H. Kim, J. M. Yoon, and J. B. Kim, “Activation of Toll-like receptor 4 is associated with insulin resistance in adipocytes,” Biochemical and Biophysical Research Communications, vol. 346, no. 3, pp. 739–745, 2006. View at Publisher · View at Google Scholar · View at Scopus
  26. A. Alisi, N. Panera, and V. Nobili, “Toll-like receptor 4: a starting point for proinflammatory signals in fatty liver disease,” Hepatology, vol. 51, no. 2, pp. 714–715, 2010. View at Publisher · View at Google Scholar · View at Scopus
  27. R. A. Frost, G. J. Nystrom, and C. H. Lang, “Lipopolysaccharide stimulates nitric oxide synthase-2 expression in murine skeletal muscle and C2C12 myoblasts via Toll-like receptor-4 and c-Jun NH2-terminal kinase pathways,” American Journal of Physiology—Cell Physiology, vol. 287, no. 6, pp. C1605–C1615, 2004. View at Publisher · View at Google Scholar · View at Scopus
  28. H. Madhumitha, V. Mohan, N. P. Kumar, R. Pradeepa, S. Babu, and V. Aravindhan, “Impaired toll-like receptor signalling in peripheral B cells from newly diagnosed type-2 diabetic subjects,” Cytokine, vol. 76, no. 2, pp. 253–259, 2015. View at Publisher · View at Google Scholar · View at Scopus
  29. K. Edfeldt, J. Swedenborg, G. K. Hansson, and Z.-Q. Yan, “Expression of toll-like receptors in human atherosclerotic lesions: a possible pathway for plaque activation,” Circulation, vol. 105, no. 10, pp. 1158–1161, 2002. View at Google Scholar · View at Scopus
  30. M. B. Fessler, L. L. Rudel, and J. M. Brown, “Toll-like receptor signaling links dietary fatty acids to the metabolic syndrome,” Current Opinion in Lipidology, vol. 20, no. 5, pp. 379–385, 2009. View at Publisher · View at Google Scholar · View at Scopus
  31. J.-G. Wang and M. Aikawa, “Toll-like receptors and Src-family kinases in atherosclerosis—focus on macrophages,” Circulation Journal, vol. 79, no. 11, pp. 2332–2334, 2015. View at Publisher · View at Google Scholar · View at Scopus
  32. J. Brown, H. Wang, G. N. Hajishengallis, and M. Martin, “TLR-signaling networks: an integration of adaptor molecules, kinases, and cross-talk,” Journal of Dental Research, vol. 90, no. 4, pp. 417–427, 2011. View at Publisher · View at Google Scholar · View at Scopus
  33. P. J. Hertzog, L. A. O'Neill, and J. A. Hamilton, “The interferon in TLR signaling: more than just antiviral,” Trends in Immunology, vol. 24, no. 10, pp. 534–539, 2003. View at Publisher · View at Google Scholar · View at Scopus
  34. A. Zeytun, A. Chaudhary, P. Pardington, R. B. Cary, and G. Gupta, “Induction of cytokines and chemokines by toll-like receptor signaling: strategies for control of infammation,” Critical Reviews in Immunology, vol. 30, no. 1, pp. 53–67, 2010. View at Publisher · View at Google Scholar · View at Scopus
  35. R. Samarasinghe, P. Tailor, T. Tamura, T. Kaisho, S. Akira, and K. Ozato, “Induction of an anti-inflammatory cytokine, IL-10, in dendritic cells after toll-like receptor signaling,” Journal of Interferon & Cytokine Research, vol. 26, no. 12, pp. 893–900, 2006. View at Publisher · View at Google Scholar · View at Scopus
  36. J. Chang, S. L. Kunkel, and C.-H. Chang, “Negative regulation of MyD88-dependent signaling by IL-10 in dendritic cells,” Proceedings of the National Academy of Sciences of the United States of America, vol. 106, no. 43, pp. 18327–18332, 2009. View at Publisher · View at Google Scholar · View at Scopus
  37. L. Franchi, N. Warner, K. Viani, and G. Nuñez, “Function of Nod-like receptors in microbial recognition and host defense,” Immunological Reviews, vol. 227, no. 1, pp. 106–128, 2009. View at Publisher · View at Google Scholar · View at Scopus
  38. H. Tada, S. Aiba, K.-I. Shibata, T. Ohteki, and H. Takada, “Synergistic effect of Nod1 and Nod2 agonists with toll-like receptor agonists on human dendritic cells to generate interleukin-12 and T helper type 1 cells,” Infection and Immunity, vol. 73, no. 12, pp. 7967–7976, 2005. View at Publisher · View at Google Scholar · View at Scopus
  39. E. Voss, J. Wehkamp, K. Wehkamp, E. F. Stange, J. M. Schröder, and J. Harder, “NOD2/CARD15 mediates induction of the antimicrobial peptide human beta-defensin-2,” The Journal of Biological Chemistry, vol. 281, no. 4, pp. 2005–2011, 2006. View at Publisher · View at Google Scholar · View at Scopus
  40. Y. Ogura, N. Inohara, A. Benito, F. F. Chen, S. Yamaoka, and G. Núñez, “Nod2, a Nod1/Apaf-1 family member that is restricted to monocytes and activates NF-κB,” The Journal of Biological Chemistry, vol. 276, no. 7, pp. 4812–4818, 2001. View at Publisher · View at Google Scholar · View at Scopus
  41. J. H. Fritz, R. L. Ferrero, D. J. Philpott, and S. E. Girardin, “Nod-like proteins in immunity, inflammation and disease,” Nature Immunology, vol. 7, no. 12, pp. 1250–1257, 2006. View at Publisher · View at Google Scholar · View at Scopus
  42. H. Wen, E. A. Miao, and J. P.-Y. Ting, “Mechanisms of NOD-like receptor-associated inflammasome activation,” Immunity, vol. 39, no. 3, pp. 432–441, 2013. View at Publisher · View at Google Scholar · View at Scopus
  43. T. Watanabe, N. Asano, A. Kitani, I. J. Fuss, T. Chiba, and W. Strober, “Activation of type I IFN signaling by NOD1 mediates mucosal host defense against Helicobacter pylori infection,” Gut Microbes, vol. 2, no. 1, pp. 61–65, 2011. View at Publisher · View at Google Scholar · View at Scopus
  44. B. Prajapati, P. K. Jena, P. Rajput, K. Purandhar, and S. Seshadri, “Understanding and modulating the Toll like Receptors (TLRs) and NOD like Receptors (NLRs) cross talk in type 2 diabetes,” Current Diabetes Reviews, vol. 10, no. 3, pp. 190–200, 2014. View at Publisher · View at Google Scholar · View at Scopus
  45. L. Zhao, P. Hu, Y. Zhou, J. Purohit, and D. Hwang, “NOD1 activation induces proinflammatory gene expression and insulin resistance in 3T3-L1 adipocytes,” American Journal of Physiology—Endocrinology and Metabolism, vol. 301, no. 4, pp. E587–E598, 2011. View at Publisher · View at Google Scholar · View at Scopus
  46. A. K. Tamrakar, J. D. Schertzer, T. T. Chiu et al., “NOD2 activation induces muscle cell-autonomous innate immune responses and insulin resistance,” Endocrinology, vol. 151, no. 12, pp. 5624–5637, 2010. View at Publisher · View at Google Scholar · View at Scopus
  47. X. Wan, C. Xu, Y. Lin et al., “Uric acid regulates hepatic steatosis and insulin resistance through the NLRP3 inflammasome-dependent mechanism,” Journal of Hepatology, vol. 64, no. 4, pp. 925–932, 2016. View at Publisher · View at Google Scholar · View at Scopus
  48. A. Shiny, B. Regin, V. Balachandar et al., “Convergence of innate immunity and insulin resistance as evidenced by increased nucleotide oligomerization domain (NOD) expression and signaling in monocytes from patients with type 2 diabetes,” Cytokine, vol. 64, no. 2, pp. 564–570, 2013. View at Publisher · View at Google Scholar · View at Scopus
  49. J. D. Schertzer, A. K. Tamrakar, J. G. Magalhães et al., “NOD1 activators link innate immunity to insulin resistance,” Diabetes, vol. 60, no. 9, pp. 2206–2215, 2011. View at Publisher · View at Google Scholar · View at Scopus
  50. P. Prieto, M. T. Vallejo-Cremades, G. Benito et al., “NOD1 receptor is up-regulated in diabetic human and murine myocardium,” Clinical Science, vol. 127, no. 12, pp. 665–677, 2014. View at Publisher · View at Google Scholar · View at Scopus
  51. J. D. Laman, A. H. Schoneveld, F. L. Moll, M. Van Meurs, and G. Pasterkamp, “Significance of peptidoglycan, a proinflammatory bacterial antigen in atherosclerotic arteries and its association with vulnerable plaques,” American Journal of Cardiology, vol. 90, no. 2, pp. 119–123, 2002. View at Publisher · View at Google Scholar · View at Scopus
  52. H. Nishio, S. Kanno, S. Onoyama et al., “Nod1 ligands induce site-specific vascular inflammation,” Arteriosclerosis, Thrombosis, and Vascular Biology, vol. 31, no. 5, pp. 1093–1099, 2011. View at Publisher · View at Google Scholar · View at Scopus
  53. M. Fernández-Velasco, P. Prieto, V. Terrón et al., “NOD1 activation induces cardiac dysfunction and modulates cardiac fibrosis and cardiomyocyte apoptosis,” PLoS ONE, vol. 7, no. 9, Article ID e45260, 2012. View at Publisher · View at Google Scholar · View at Scopus
  54. Y. Pan, G. Li, H. Zhong et al., “RIG-I inhibits pancreatic β cell proliferation through competitive binding of activated Src,” Scientific Reports, vol. 6, Article ID 28914, 2016. View at Publisher · View at Google Scholar
  55. A. Komuro, D. Bamming, and C. M. Horvath, “Negative regulation of cytoplasmic RNA-mediated antiviral signaling,” Cytokine, vol. 43, no. 3, pp. 350–358, 2008. View at Publisher · View at Google Scholar · View at Scopus
  56. T. B. H. Geijtenbeek and S. I. Gringhuis, “Signalling through C-type lectin receptors: shaping immune responses,” Nature Reviews Immunology, vol. 9, no. 7, pp. 465–479, 2009. View at Publisher · View at Google Scholar · View at Scopus
  57. S. Iborra and D. Sancho, “Signalling versatility following self and non-self sensing by myeloid C-type lectin receptors,” Immunobiology, vol. 220, no. 2, pp. 175–184, 2015. View at Publisher · View at Google Scholar · View at Scopus
  58. M. Ichioka, T. Suganami, N. Tsuda et al., “Increased expression of macrophage-inducible C-type lectin in adipose tissue of obese mice and humans,” Diabetes, vol. 60, no. 3, pp. 819–826, 2011. View at Publisher · View at Google Scholar · View at Scopus
  59. A. L. Neves, J. Coelho, L. Couto, A. Leite-Moreira, and R. Roncon-Albuquerque Jr., “Metabolic endotoxemia: a molecular link between obesity and cardiovascular risk,” Journal of Molecular Endocrinology, vol. 51, no. 2, pp. R51–R64, 2013. View at Publisher · View at Google Scholar · View at Scopus
  60. S. de Kort, D. Keszthelyi, and A. A. M. Masclee, “Leaky gut and diabetes mellitus: what is the link?” Obesity Reviews, vol. 12, no. 6, pp. 449–458, 2011. View at Publisher · View at Google Scholar · View at Scopus
  61. V. Aravindhan, V. Mohan, H. Madhumitha, S. Valarmathi, and S. Babu, “Increased levels of endotoxin core antibodies and decreased levels of sCD 14 indicate chronic endotoxemia in coronary artery disease (CURES-127),” Journal of Clinical & Experimental Cardiology, vol. 4, no. 9, article 264, 2013. View at Publisher · View at Google Scholar
  62. P. D. Cani, J. Amar, M. A. Iglesias et al., “Metabolic endotoxemia initiates obesity and insulin resistance,” Diabetes, vol. 56, no. 7, pp. 1761–1772, 2007. View at Publisher · View at Google Scholar · View at Scopus
  63. M. Manco, L. Putignani, and G. F. Bottazzo, “Gut microbiota, lipopolysaccharides, and innate immunity in the pathogenesis of obesity and cardiovascular risk,” Endocrine Reviews, vol. 31, no. 6, pp. 817–844, 2010. View at Publisher · View at Google Scholar · View at Scopus
  64. L. Jonasson, J. Holm, O. Skalli, G. Bondjers, and G. K. Hansson, “Regional accumulations of T cells, macrophages, and smooth muscle cells in the human atherosclerotic plaque,” Arteriosclerosis, vol. 6, no. 2, pp. 131–138, 1986. View at Publisher · View at Google Scholar · View at Scopus
  65. J. Surendar, V. Mohan, N. Pavankumar, S. Babu, and V. Aravindhan, “Increased levels of serum granulocyte-macrophage colony-stimulating factor is associated with activated peripheral dendritic cells in type 2 diabetes subjects (CURES-99),” Diabetes Technology and Therapeutics, vol. 14, no. 4, pp. 344–349, 2012. View at Publisher · View at Google Scholar · View at Scopus
  66. S. Tangvarasittichai, S. Pongthaisong, and O. Tangvarasittichai, “Tumor necrosis factor-Α, interleukin-6, C-reactive protein levels and insulin resistance associated with type 2 diabetes in abdominal obesity women,” Indian Journal of Clinical Biochemistry, vol. 31, no. 1, pp. 68–74, 2016. View at Publisher · View at Google Scholar · View at Scopus
  67. J. Spranger, A. Kroke, M. Möhlig et al., “Inflammatory cytokines and the risk to develop type 2 diabetes: results of the prospective population-based European Prospective Investigation into Cancer and Nutrition (EPIC)-Potsdam study,” Diabetes, vol. 52, no. 3, pp. 812–817, 2003. View at Publisher · View at Google Scholar · View at Scopus
  68. A. M. Miller, “Role of IL-33 in inflammation and disease,” Journal of Inflammation, vol. 8, no. 1, article 22, 2011. View at Publisher · View at Google Scholar · View at Scopus
  69. P. Miossec and J. K. Kolls, “Targeting IL-17 and TH17 cells in chronic inflammation,” Nature Reviews Drug Discovery, vol. 11, no. 10, pp. 763–776, 2012. View at Publisher · View at Google Scholar · View at Scopus
  70. A. Shimbara, P. Christodoulopoulos, A. Soussi-Gounni et al., “IL-9 and its receptor in allergic and nonallergic lung disease: increased expression in asthma,” Journal of Allergy and Clinical Immunology, vol. 105, no. 1, pp. 108–115, 2000. View at Publisher · View at Google Scholar · View at Scopus
  71. J. Louten, A. L. Rankin, Y. Li et al., “Endogenous IL-33 enhances Th2 cytokine production and T-cell responses during allergic airway inflammation,” International Immunology, vol. 23, no. 5, pp. 307–315, 2011. View at Publisher · View at Google Scholar · View at Scopus
  72. Y. Y. Wan, “Multi-tasking of helper T cells,” Immunology, vol. 130, no. 2, pp. 166–171, 2010. View at Publisher · View at Google Scholar · View at Scopus
  73. L. Pacifico, L. Di Renzo, C. Anania et al., “Increased T-helper interferon-γ-secreting cells in obese children,” European Journal of Endocrinology, vol. 154, no. 5, pp. 691–697, 2006. View at Publisher · View at Google Scholar · View at Scopus
  74. M. Wegner, H. Winiarska, T. Bobkiewicz-Kozłowska, and M. Dworacka, “IL-12 serum levels in patients with type 2 diabetes treated with sulphonylureas,” Cytokine, vol. 42, no. 3, pp. 312–316, 2008. View at Publisher · View at Google Scholar · View at Scopus
  75. J. Surendar, V. Mohan, M. M. Rao, S. Babu, and V. Aravindhan, “Increased levels of both Th1 and Th2 cytokines in subjects with metabolic syndrome (CURES-103),” Diabetes Technology and Therapeutics, vol. 13, no. 4, pp. 477–482, 2011. View at Publisher · View at Google Scholar · View at Scopus
  76. U. Kintscher, M. Hartge, K. Hess et al., “T-lymphocyte infiltration in visceral adipose tissue: a primary event in adipose tissue inflammation and the development of obesity-mediated insulin resistance,” Arteriosclerosis, Thrombosis, and Vascular Biology, vol. 28, no. 7, pp. 1304–1310, 2008. View at Publisher · View at Google Scholar · View at Scopus
  77. F. C. McGillicuddy, E. H. Chiquoine, C. C. Hinkle et al., “Interferon γ attenuates insulin signaling, lipid storage, and differentiation in human adipocytes via activation of the JAK/STAT pathway,” The Journal of Biological Chemistry, vol. 284, no. 46, pp. 31936–31944, 2009. View at Publisher · View at Google Scholar · View at Scopus
  78. J. E. McLaren and D. P. Ramji, “Interferon gamma: a master regulator of atherosclerosis,” Cytokine and Growth Factor Reviews, vol. 20, no. 2, pp. 125–135, 2009. View at Publisher · View at Google Scholar · View at Scopus
  79. L. Jonasson, J. Holm, O. Skalli, G. Gabbiani, and G. K. Hansson, “Expression of class II transplantation antigen on vascular smooth muscle cells in human atherosclerosis,” The Journal of Clinical Investigation, vol. 76, no. 1, pp. 125–131, 1985. View at Publisher · View at Google Scholar · View at Scopus
  80. J. Frostegård, A.-K. Ulfgren, P. Nyberg et al., “Cytokine expression in advanced human atherosclerotic plaques: dominance of pro-inflammatory (Th1) and macrophage-stimulating cytokines,” Atherosclerosis, vol. 145, no. 1, pp. 33–43, 1999. View at Publisher · View at Google Scholar · View at Scopus
  81. S. Gupta, A. M. Pablo, X.-C. Jiang, N. Wang, A. R. Tall, and C. Schindler, “IFN-gamma potentiates atherosclerosis in ApoE knock-out mice,” The Journal of Clinical Investigation, vol. 99, no. 11, pp. 2752–2761, 1997. View at Publisher · View at Google Scholar · View at Scopus
  82. W. A. LaFramboise, R. Dhir, L. A. Kelly et al., “Serum protein profiles predict coronary artery disease in symptomatic patients referred for coronary angiography,” BMC Medicine, vol. 10, article 157, 2012. View at Publisher · View at Google Scholar · View at Scopus
  83. H. Madhumitha, V. Mohan, M. Deepa, S. Babu, and V. Aravindhan, “Increased Th1 and suppressed Th2 serum cytokine levels in subjects with diabetic coronary artery disease,” Cardiovascular Diabetology, vol. 13, article 1, 2014. View at Publisher · View at Google Scholar · View at Scopus
  84. L. Q. Jiang, N. Franck, B. Egan et al., “Autocrine role of interleukin-13 on skeletal muscle glucose metabolism in type 2 diabetic patients involves microRNA let-7,” American Journal of Physiology—Endocrinology and Metabolism, vol. 305, no. 11, pp. E1359–E1366, 2013. View at Publisher · View at Google Scholar · View at Scopus
  85. Y.-H. Chang, K.-T. Ho, S.-H. Lu, C.-N. Huang, and M.-Y. Shiau, “Regulation of glucose/lipid metabolism and insulin sensitivity by interleukin-4,” International Journal of Obesity, vol. 36, no. 7, pp. 993–998, 2012. View at Publisher · View at Google Scholar · View at Scopus
  86. S. Winer, Y. Chan, G. Paltser et al., “Normalization of obesity-associated insulin resistance through immunotherapy,” Nature Medicine, vol. 15, no. 8, pp. 921–929, 2009. View at Publisher · View at Google Scholar · View at Scopus
  87. G. Anand, R. Vasanthakumar, V. Mohan, S. Babu, and V. Aravindhan, “Increased IL-12 and decreased IL-33 serum levels are associated with increased Th1 and suppressed Th2 cytokine profile in patients with diabetic nephropathy (CURES-134),” International Journal of Clinical and Experimental Pathology, vol. 7, no. 11, pp. 8008–8015, 2015. View at Google Scholar
  88. Z. Mallat, S. Taleb, H. Ait-Oufella, and A. Tedgui, “The role of adaptive T cell immunity in atherosclerosis,” Journal of Lipid Research, vol. 50, pp. S364–S369, 2009. View at Publisher · View at Google Scholar · View at Scopus
  89. J. L. Fernandes, R. L. Mamoni, J. L. Orford et al., “Increased Th1 activity in patients with coronary artery disease,” Cytokine, vol. 26, no. 3, pp. 131–137, 2004. View at Publisher · View at Google Scholar · View at Scopus
  90. L. A. Tesmer, S. K. Lundy, S. Sarkar, and D. A. Fox, “Th17 cells in human disease,” Immunological Reviews, vol. 223, no. 1, pp. 87–113, 2008. View at Publisher · View at Google Scholar · View at Scopus
  91. P. Kumar, K. Natarajan, and N. Shanmugam, “High glucose driven expression of pro-inflammatory cytokine and chemokine genes in lymphocytes: molecular mechanisms of IL-17 family gene expression,” Cellular Signalling, vol. 26, no. 3, pp. 528–539, 2014. View at Publisher · View at Google Scholar · View at Scopus
  92. M. K. Arababadi, R. Nosratabadi, G. Hassanshahi et al., “Nephropathic complication of type-2 diabetes is following pattern of autoimmune diseases?” Diabetes Research and Clinical Practice, vol. 87, no. 1, pp. 33–37, 2010. View at Publisher · View at Google Scholar · View at Scopus
  93. R. Vasanthakumar, V. Mohan, G. Anand, M. Deepa, S. Babu, and V. Aravindhan, “Serum IL-9, IL-17, and TGF-β levels in subjects with diabetic kidney disease (CURES-134),” Cytokine, vol. 72, no. 1, pp. 109–112, 2015. View at Publisher · View at Google Scholar · View at Scopus
  94. N. Afzal, K. Javaid, W. Sami et al., “Inverse relationship of serum IL-17 with type-II diabetes retinopathy,” Clinical Laboratory, vol. 59, no. 11-12, pp. 1311–1317, 2013. View at Publisher · View at Google Scholar · View at Scopus
  95. E. Smith, K.-M. R. Prasad, M. Butcher et al., “Blockade of interleukin-17A results in reduced atherosclerosis in apolipoprotein E-deficient mice,” Circulation, vol. 121, no. 15, pp. 1746–1755, 2010. View at Publisher · View at Google Scholar · View at Scopus
  96. C. Erbel, T. J. Dengler, S. Wangler et al., “Expression of IL-17A in human atherosclerotic lesions is associated with increased inflammation and plaque vulnerability,” Basic Research in Cardiology, vol. 106, no. 1, pp. 125–134, 2011. View at Publisher · View at Google Scholar · View at Scopus
  97. J. Xing, Y. Wu, and B. Ni, “Th9: a new player in asthma pathogenesis?” Journal of Asthma, vol. 48, no. 2, pp. 115–125, 2011. View at Publisher · View at Google Scholar · View at Scopus
  98. H. Hang, S. Yuan, Q. Yang, D. Yuan, and Q. Liu, “Multiplex bead array assay of plasma cytokines in type 2 diabetes mellitus with diabetic retinopathy,” Molecular Vision, vol. 20, pp. 1137–1145, 2014. View at Google Scholar · View at Scopus
  99. W. Zhang, T. Tang, D. Nie et al., “IL-9 aggravates the development of atherosclerosis in ApoE−/− mice,” Cardiovascular Research, vol. 106, no. 3, pp. 453–464, 2015. View at Publisher · View at Google Scholar · View at Scopus
  100. I. Gregersen, M. Skjelland, S. Holm et al., “Increased systemic and local interleukin 9 levels in patients with carotid and coronary atherosclerosis,” PLoS ONE, vol. 8, no. 8, Article ID e72769, 2013. View at Publisher · View at Google Scholar · View at Scopus
  101. D. Mathis and S. E. Shoelson, “Immunometabolism: an emerging frontier,” Nature Reviews Immunology, vol. 11, no. 2, pp. 81–83, 2011. View at Publisher · View at Google Scholar · View at Scopus